Asymptomatic testing of hospital admissions for SARS-CoV-2: Is it OK to stop?
Karen BrustTakaaki KobayashiDaniel J DiekemaPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Universal SARS-CoV-2 testing of all persons admitted to acute care hospitals has become common practice. We describe why one hospital discontinued this practice after weighing potential benefits against known harms. Considerations around the benefits shifted as we saw a decline in SARS-CoV-2 community transmission and COVID-19 severity of illness, increased availability of vaccines and treatments, and better understood the many other transmission pathways in the healthcare environment. Considerations around harms included the additional strain on laboratory and infection prevention resources, and several unintended adverse consequences of admission screening for patients, including unnecessary isolation, antiviral treatments, and delays in care delivery. Poor test performance for detection of infectiousness also played a significant role in determining to stop universal screening. No increase in hospital-onset COVID-19 has been documented since discontinuation of admission testing. We continue to apply other established layers of prevention while monitoring for any change in incidence of within-facility transmission of SARS-CoV-2.
Keyphrases
- sars cov
- healthcare
- acute care
- respiratory syndrome coronavirus
- end stage renal disease
- emergency department
- primary care
- newly diagnosed
- ejection fraction
- risk factors
- adverse drug
- chronic kidney disease
- peritoneal dialysis
- mental health
- prognostic factors
- risk assessment
- climate change
- electronic health record
- social media
- health information
- loop mediated isothermal amplification